1. Eli Lilly is investing in radiopharmaceuticals for cancer care and has a potential blockbuster drug, Kisunla, for early Alzheimer’s disease.
2. The company is utilizing artificial intelligence to accelerate drug development and has successful GLP-1 drugs generating billions in revenue.
3. Eli Lilly’s collaboration with Nvidia for AI-powered drug discovery could lead to more efficient and effective treatments, unlocking growth opportunities.
4. Despite recent stock performance, Eli Lilly remains a strong growth investment with promising prospects and potential to join the trillion-dollar club.
5. Consideration of investing in Eli Lilly should be weighed against other top stock picks from the Motley Fool Stock Advisor team for potential high returns.

Read more at Nasdaq: 3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs